Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
Experimental and Clinical Endocrinology & Diabetes · 01.04.2023 · 131 (04) · 205-215
DOI: 10.1055/a-2007-2061 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.04.2023. Verfasst von Markus Menzen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gemeinschaftskrankenhaus Bonn, Innere Medizin - Diabetologie und Endokrinologie, Bonn, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world evidence.
Objective
SURE Germany evaluated once-weekly semaglutide in a real-world type 2 diabetes patient population. Design/setting The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide.
Intervention
Once-weekly semaglutide was prescribed at the physicians’ discretion. Main outcomes The primary endpoint was change in glycated haemoglobin from baseline to end-of-study (~30 weeks). Secondary endpoints included changes in body weight and patient-reported outcomes. All adverse events were systematically collected and reported, including patient-reported documented and/or severe hypoglycaemia.
Results
Of 779 patients in the full analysis set, 669 (85.9%) completed the study on treatment with semaglutide, comprising the effectiveness analysis set. In this data set, estimated mean changes in glycated haemoglobin and body weight from baseline to end-of-study were –1.0%point (–10.9 mmol/mol; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gemeinschaftskrankenhaus Bonn, Innere Medizin - Diabetologie und Endokrinologie, Bonn, Germany.
- Novo Nordisk A/S, Søborg, Denmark.
- Novo Nordisk Pharma GmbH, Mainz, Germany.
- MVZ im Altstadt-Carree Fulda GmbH, Fulda, Germany.
- Cardio-metabolic Institute, Villingen, Germany.
ORCID-Profile: Markus Menzen
Förderung
- Novo Nordisk
Zitieren
APA
Menzen, M., Berentzen, T. L., Catarig, A. M., Pieperhoff, S., Simon, J., & Jacob, S. (2023). Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany. Experimental and Clinical Endocrinology & Diabetes, 131(04), 205-215. https://doi.org/10.1055/a-2007-2061
Vancouver
Menzen M, Berentzen TL, Catarig AM, Pieperhoff S, Simon J, Jacob S. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany. Experimental and Clinical Endocrinology & Diabetes. 2023;131(04):205-215. doi:10.1055/a-2007-2061
BibTeX
@article{Menzen2023,
author = {Menzen, Markus and Berentzen, Tina Landsvig and Catarig, Andrei-Mircea and Pieperhoff, Sebastian and Simon, Jörg and Jacob, Stephan},
title = {Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2023},
volume = {131},
number = {04},
pages = {205--215},
doi = {10.1055/a-2007-2061}
}
EUVIMED